

# Fragile X Syndrome - Pipeline Review, H1 2020

<https://marketpublishers.com/r/PBD38472D01EN.html>

Date: March 2020

Pages: 188

Price: US\$ 2,000.00 (Single User License)

ID: PBD38472D01EN

## Abstracts

Fragile X Syndrome - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Fragile X Syndrome - Pipeline Review, H1 2020, provides an overview of the Fragile X Syndrome (Genetic Disorders) pipeline landscape.

Fragile X syndrome is a genetic condition that causes a range of developmental problems including learning disabilities and cognitive impairment. Fragile X syndrome is caused by a change in a gene called FMR1. Fragile X syndrome occurs both in male and female. Symptoms include delay in crawling, walking, or twisting, hyperactive or impulsive behavior, speech and language delay and intellectual disability.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Fragile X Syndrome - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Fragile X Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fragile X Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fragile X Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III,

Phase II, Phase I and Preclinical stages are 2, 5, 2 and 18 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.

Fragile X Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Fragile X Syndrome (Genetic Disorders).

The pipeline guide reviews pipeline therapeutics for Fragile X Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Fragile X Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Fragile X Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Fragile X Syndrome (Genetic Disorders)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Fragile X Syndrome (Genetic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Fragile X Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Fragile X Syndrome - Overview

Fragile X Syndrome - Therapeutics Development

Fragile X Syndrome - Therapeutics Assessment

Fragile X Syndrome - Companies Involved in Therapeutics Development

Fragile X Syndrome - Drug Profiles

Fragile X Syndrome - Dormant Projects

Fragile X Syndrome - Discontinued Products

Fragile X Syndrome - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Fragile X Syndrome, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Companies, H1 2020 (Contd..1), H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Fragile X Syndrome - Pipeline by Anavex Life Sciences Corp, H1 2020  
Fragile X Syndrome - Pipeline by Autifony Therapeutics Ltd, H1 2020  
Fragile X Syndrome - Pipeline by Confluence Pharmaceuticals LLC, H1 2020  
Fragile X Syndrome - Pipeline by DRI Biosciences Corp, H1 2020  
Fragile X Syndrome - Pipeline by Epigen Biosciences Inc, H1 2020  
Fragile X Syndrome - Pipeline by GlaxoSmithKline Plc, H1 2020  
Fragile X Syndrome - Pipeline by GW Pharmaceuticals Plc, H1 2020  
Fragile X Syndrome - Dormant Projects, H1 2020  
Fragile X Syndrome - Dormant Projects, H1 2020 (Contd..1), H1 2020  
Fragile X Syndrome - Discontinued Products, H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Fragile X Syndrome, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Routes of Administration, H1 2020  
Number of Products by Stage and Routes of Administration, H1 2020  
Number of Products by Molecule Types, H1 2020  
Number of Products by Stage and Molecule Types, H1 2020

### COMPANIES MENTIONED

Anavex Life Sciences Corp  
Autifony Therapeutics Ltd  
Confluence Pharmaceuticals LLC  
DRI Biosciences Corp  
Epigen Biosciences Inc  
GlaxoSmithKline Plc  
GW Pharmaceuticals Plc  
Healx Ltd  
Lysogene SAS  
Marinus Pharmaceuticals Inc  
Neuren Pharmaceuticals Ltd  
Neuron Biopharma SA  
Neurotrope Bioscience Inc  
Novartis AG  
Ovid Therapeutics Inc  
Prous Institute for Biomedical Research SA  
RespireRx Pharmaceuticals Inc  
Sage Therapeutics Inc  
Sentinel Oncology Ltd  
Seropeutics LLC  
Takeda Pharmaceutical Co Ltd

Tetra Therapeutics  
Zynerba Pharmaceuticals Inc

## I would like to order

Product name: Fragile X Syndrome - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/PBD38472D01EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/PBD38472D01EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970